Skip to main content
Kexing Biopharm logo

Kexing Biopharm — Investor Relations & Filings

Ticker · 688136 ISIN · CNE100006ZG6 LEI · 529900Z34Q1M9A907771 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2025-08-15 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688136

About Kexing Biopharm

https://www.kexingbiopharm.com/

Kexing Biopharm is an innovative biopharmaceutical enterprise engaged in the research, development, production, and sales of recombinant protein drugs and micro-ecological preparations. The company focuses on developing treatments for therapeutic areas including kidney diseases, oncology, antiviral therapy, autoimmune disorders, metabolic diseases, and degenerative diseases. A key product in its portfolio is Erythropoietin Injection. Kexing Biopharm maintains a comprehensive quality system that aligns with international standards, covering the entire drug lifecycle from production and quality control to release and transportation, ensuring the continuous and stable manufacturing of safe and effective medicines.

Recent filings

Filing Released Lang Actions
第二届董事会第二十八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of 科兴生物制药股份有限公司 (Kexing Biopharmaceutical Co., Ltd.). It details the meeting date, attendance, and specific decisions made by the board, such as approval of funding loans to subsidiaries, approval of foreign exchange derivative transactions, signing of related party agreements, issuance of innovation bonds, and adoption of certain management systems. The document is titled as a "董事会会议决议公告" which translates to "Board of Directors Meeting Resolution Announcement." It does not contain financial statements or detailed financial data but rather reports on board decisions and approvals. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management. The document length is 2158 characters, relatively short and focused on board resolutions, not a full report or financial disclosure. Therefore, the correct classification is MANG with high confidence.
2025-08-15 Chinese
外汇衍生品交易管理制度
Governance Information Classification · 95% confidence The document is titled as a management system for foreign exchange derivative trading by 科兴生物制药股份有限公司 (Sino Biopharmaceutical Limited). It outlines the principles, approval authorities, management processes, risk reporting, information disclosure, and archival management related to the company's foreign exchange derivative trading activities. There are no financial statements, earnings data, or audit results presented. The document is a detailed internal policy or governance document related to risk management and operational procedures for derivative trading. It is not an announcement, report publication, or certification. It fits best under Governance Information (CGR) as it details internal rules and governance practices related to foreign exchange derivative trading management. The document length is 3939 characters, which is substantial and contains detailed governance content rather than a brief announcement or regulatory filing. Therefore, the classification is CGR with high confidence.
2025-08-15 Chinese
关于签署关联交易协议补充协议的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the signing of a supplementary agreement for a related party transaction involving lease agreements between the company's subsidiaries and a related party. It includes details about the transaction, the parties involved, the approval process by the board and committees, and the impact on the company. The document is relatively short (4085 characters) and focuses on disclosure of a specific transaction rather than financial results or comprehensive reports. It does not contain financial statements or detailed financial analysis. It is a regulatory announcement about a related party transaction, which fits best under Regulatory Filings (RNS) as it does not match other more specific categories like Annual Report, Interim Report, or Capital/Financing Update.
2025-08-15 Chinese
关于召开2025年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about the convening of the 2025 first extraordinary general meeting (临时股东大会) of the company 科兴生物制药股份有限公司. It includes information about the meeting date, voting methods, agenda items (such as board elections and amendments to company articles), registration procedures, and proxy forms. The content is focused on the organization and conduct of a shareholders' meeting, including voting instructions and candidate information for board elections. There are no financial statements, earnings data, or audit information presented. The document is not a report of results or minutes but a formal announcement and notice of the meeting and its agenda. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or Proxy Solicitation & Information Statement (PSI). However, since this document is a notice of the meeting and includes proxy forms and detailed voting instructions, it aligns best with Proxy Solicitation & Information Statement (PSI), which covers materials sent to shareholders to provide information and request votes for meetings. The document length (6676 characters) and detailed content support this classification rather than a brief announcement or a report of voting results after the meeting.
2025-08-11 Chinese
中国国际金融股份有限公司关于科兴生物制药股份有限公司股东向特定机构投资者询价转让股份的核查报告
Audit Report / Information Classification · 95% confidence The document is a detailed report from China International Capital Corporation Limited regarding the verification of a shareholder's inquiry-based transfer of shares to specific institutional investors of SciClone Pharmaceuticals. It includes detailed descriptions of the transfer process, pricing principles, participant qualifications, and compliance with regulatory guidelines. The document is titled as a "核查报告" (verification report) and focuses on the legality, fairness, and compliance of the share transfer process. It is not an announcement of a report publication, nor is it a general regulatory filing or a financial report like an annual or interim report. The content aligns with an audit or verification report related to a specific transaction, which fits the category of Audit Report / Information (AR). The document length (6365 characters) supports it being a full report rather than a brief announcement. Therefore, the most appropriate classification is AR (Audit Report / Information). Q3 2025
2025-08-05 Chinese
股东询价转让结果报告书暨持股5%以上股东权益变动触及1%整数倍的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a detailed announcement regarding a shareholder's transfer of shares and changes in shareholding percentages. It includes specifics about the transfer price, number of shares transferred, shareholder identities, and the impact on control percentages. It also contains a verification report from an intermediary institution confirming the fairness and compliance of the transfer process. The document focuses on changes in significant share ownership levels, specifically noting that the shareholding change touches a 1% threshold. There is no indication that this is a full financial report, earnings release, or management discussion. The content aligns with the definition of a Major Shareholding Notification, which involves notifying changes in significant share ownership levels crossing thresholds. The document length and detail confirm it is not a brief announcement or a report publication notice but a substantive notification of shareholding changes.
2025-08-05 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.